Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

The TODAY Study: An NIH Perspective on Its Implications for Research

  1. Barbara L. Linder, MD, PHD⇑,
  2. Judith E. Fradkin, MD and
  3. Griffin P. Rodgers, MD
  1. Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
  1. Corresponding author: Barbara L. Linder, linderb{at}mail.nih.gov.
Diabetes Care 2013 Jun; 36(6): 1775-1776. https://doi.org/10.2337/dc13-0707
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Once referred to as adult-onset diabetes, type 2 diabetes (T2D) has emerged in youth as a consequence of the worldwide increase in obesity. The development of T2D among young individuals has significant public health consequences as these youth are likely to manifest the complications of diabetes, including retinopathy, nephropathy, neuropathy, and cardiovascular disease, at a time that should be the most active and productive of their lives.

In response to the emergence of T2D among youth in the mid-1990s, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health sought to foster research to understand and address this public health threat. Since most of our knowledge about the epidemiology of T2D in the pediatric population was based on small clinic-based reports, NIDDK partnered with the Centers for Disease Control and Prevention (CDC) to establish the SEARCH for Diabetes in Youth Study to provide population-based statistics for diabetes in U.S. youth (1). SEARCH data from 2002–2003 indicated that approximately 3,700 youth were being diagnosed annually with T2D (2). T2D is rarely seen in children younger than 10 years. In non-Hispanic white youth 10–19 years of age, T2D represents 15% of the new cases of diabetes. However, T2D predominates in 10- to 19-year-old minority youth, representing 86% of the new cases among American Indians, 70% among Asian/Pacific Islanders, 58% in blacks, and 46% in Hispanics. SEARCH is continuing to ascertain diabetes incidence and is poised to provide critical information on trends in the incidence for both type 1 diabetes and T2D among U.S. youth. SEARCH has also described in great detail the characteristics of U.S. youth with T2D. Perhaps of greatest concern is that 27% of the youth with T2D enrolled in SEARCH had poor glycemic control (hemoglobin A1c ≥9.5%), with the highest rates among those youth from racial/ethnic minority groups (3). These data highlight the need to more effectively treat T2D in youth.

To understand treatment strategies, NIDDK funded the TODAY study (Treatment Options for type 2 Diabetes in Adolescents and Youth) (4). Providers were unsure of how to approach treatment, especially since metformin is the only oral hypoglycemic agent approved for use in children. In addition, adolescence presents special challenges, which means that effective treatments in adults may not be easily transferable to youth. Finally, it was not known whether the pathophysiology and clinical course would be the same when T2D occurs at a young age.

The primary results of the TODAY study, reported last year, demonstrated that T2D may have a much more aggressive course in youth, with approximately half of patients unable to maintain glycemic control on metformin monotherapy despite good medication compliance (5). The data on insulin resistance and secretion derived from serial oral glucose tolerance tests in the TODAY study, published in this issue of Diabetes Care (6), suggest early and rapid deterioration of β-cell function in these youth compared with data published on adult individuals with newly diagnosed T2D. These data suggest the need to intervene aggressively and early in youth. Further analysis of the TODAY data may help identify those youth most likely to fail; research is also needed to determine whether high-risk youth could benefit from more intensive, early interventions to prevent the progression to diabetes. The extent to which it is possible to preserve β-cell function early in the course of T2D is not known. NIDDK has recently established the Restore Insulin Secretion (RISE) consortium to study approaches to maintain insulin secretion in adults and children with prediabetes or newly diagnosed T2D. Investigators will use hyperglycemic clamp studies to document the effects of various therapies, including pharmacologic treatments and bariatric surgery, on insulin sensitivity and secretion. Recent data (7) show that dedifferentiation, rather than cell death, may drive β-cell dysfunction in a mouse model of diabetes, suggesting that β-cells may not be irretrievably lost.

TODAY data also highlight the race/ethnic disparities seen in T2D. Both TODAY and SEARCH data have shown that, as in adults, T2D disproportionately affects youth from minority groups. The TODAY cohort (8) was predominately minority (32% African American, 41% Hispanic, 6% American Indian) and of low socioeconomic status (42% with household income <$25,000); the majority of the TODAY participants came from single-parent households. The economic and psychosocial barriers faced by these families make aggressive glucose control a challenge. The TODAY study previously reported that almost 15% of the participants reported depressive symptoms at baseline (9). Data on poor risk factor control and emerging microvascular disease in this population, detailed in the articles published in this issue of Diabetes Care (10–12), are ominous—especially in the context of a rigorous clinical trial with extensive individual attention provided and a population selected for its ability to comply with protocol requirements—and may portend poor outcomes, including early cardiovascular disease. Further follow-up of the TODAY participants will provide valuable information about the development of complications in this population.

The challenges in effectively treating T2D in youth highlight the need for effective prevention of obesity and diabetes. The NIDDK-supported Diabetes Prevention Program (DPP) clearly established the effectiveness of weight loss or metformin in delaying the onset of T2D in individuals at high risk (13). The school-based HEALTHY study, funded by NIDDK with support from the American Diabetes Association, demonstrated that a population-based program could lower rates of obesity and hyperinsulinemia in middle school–aged children, although the combined rate of overweight and obesity fell in both the control and intervention schools (14). Despite these past successes, the TODAY lifestyle program did not lead to sustained weight loss, better body composition (15), or improved glycemic control. Further behavioral research is needed to develop approaches that will lead to successful lifestyle changes in adolescents, especially those of low socioeconomic status who may face barriers to healthy eating and have limited opportunities for physical activity. The need is imperative to promote research to understand how to establish healthy habits at a young age rather than trying to correct “bad” habits later on.

To prevent obesity and T2D in youth requires tackling another critical issue—the role of metabolic imprinting in contributing to risk. Numerous studies have established that diabetes during pregnancy confers an increased risk of obesity and diabetes in offspring. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) with support from NIDDK, demonstrated adverse perinatal outcomes at levels of hyperglycemia that are lower than established thresholds for gestational diabetes mellitus (16). NIDDK, with support from NICHD, recently launched a follow-up study of 7,000 mother-child HAPO dyads to examine whether hyperglycemia during pregnancy, less severe than diabetes, leads to adverse metabolic outcomes in the offspring at 8–12 years of age. The TODAY data reported in this issue highlight the need to tackle the effects of diabetes during pregnancy; during the TODAY study, there were 62 pregnancies occurring in 45 participants with six infants having congenital anomalies (17). Further research is needed to understand whether treatment during pregnancy can effectively break the vicious cycle of metabolic imprinting. To address this issue, NIDDK in collaboration with NICHD; the National Heart, Lung, and Blood Institute; the National Center for Complementary and Alternative Medicine; and the Office of Research on Women’s Health has recently launched the LIFE-Moms (Lifestyle Interventions for Expectant Moms) Study, which will test several lifestyle interventions to control weight gain during pregnancy in women who are overweight or obese. The investigators will also follow the women and their offspring up to 1 year after delivery to explore correlations between gestational weight gain and later metabolic status for both mother and baby.

T2D reduces quality of life in individuals with the disease and their families and imposes a huge economic burden on society. The results of the TODAY study lend urgency to the need to better understand the pathophysiology of T2D in youth so that better prevention and treatment strategies can be developed and effectively translated into practice. NIH is committed to building on the TODAY study findings through further research to understand the disease process and develop interventions that can modulate it.

Acknowledgments

No potential conflicts of interest relevant to this article were reported.

The authors thank the TODAY investigators for their dedication in recruiting and maintaining the TODAY cohort. They are indebted to the TODAY participants and their families for their contributions to understanding the course of T2D in youth.

Footnotes

  • See accompanying articles beginning on p. 1732

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. SEARCH Study Group
    . SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials 2004;25:458–471pmid:15465616
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. The Writing Group for the SEARCH for Diabetes in Youth Study Group
    . Incidence of diabetes in youth in the United States. JAMA 2007;297:2716–2724pmid:17595272
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Petitti DB,
    2. Klingensmith GJ,
    3. Bell RA
    , et al.; SEARCH for Diabetes in Youth Study Group. Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr 2009;155:668–672pmid:19643434
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Zeitler P,
    2. Epstein L,
    3. Grey M,
    4. et al.,
    5. TODAY Study Group
    . Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8:74–87pmid:17448130
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Zeitler P,
    2. Hirst K,
    3. Pyle L,
    4. et al.,
    5. TODAY Study Group
    . A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247–2256pmid:22540912
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. TODAY Study Group
    . Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749–1757
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Talchai C,
    2. Xuan S,
    3. Lin HV,
    4. Sussel L,
    5. Accili D
    . Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 2012;150:1223–1234pmid:22980982
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Copeland KC,
    2. Zeitler P,
    3. Geffner M,
    4. et al.,
    5. TODAY Study Group
    . Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96:159–167pmid:20962021
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Anderson BJ,
    2. Edelstein S,
    3. Abramson NW,
    4. et al
    . Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care 2011;34:2205–2207pmid:21836107
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. TODAY Study Group
    . Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013;36:1735–1741
    OpenUrlAbstract/FREE Full Text
    1. TODAY Study Group
    . Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care 2013;36:1772–1774
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. TODAY Study Group
    . Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013;36:1758–1764
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Knowler WC,
    2. Barrett-Connor E,
    3. Fowler SE,
    4. et al.,
    5. Diabetes Prevention Program Research Group
    . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403pmid:11832527
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Foster GD,
    2. Linder B,
    3. Baranowski T,
    4. et al.,
    5. HEALTHY Study Group
    . A school-based intervention for diabetes risk reduction. N Engl J Med 2010;363:443–453pmid:20581420
    OpenUrlCrossRefPubMed
  14. ↵
    1. TODAY Study Group
    . Treatment effects on measures of body composition in the TODAY clinical trial. Diabetes Care 2013;36:1742–1748
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Metzger BE,
    2. Lowe LP,
    3. Dyer AR,
    4. et al.,
    5. HAPO Study Cooperative Research Group
    . Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991–2002pmid:18463375
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. TODAY Study Group
    . Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care 2013;36:1765–1771
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes Care: 36 (6)

In this Issue

June 2013, 36(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The TODAY Study: An NIH Perspective on Its Implications for Research
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The TODAY Study: An NIH Perspective on Its Implications for Research
Barbara L. Linder, Judith E. Fradkin, Griffin P. Rodgers
Diabetes Care Jun 2013, 36 (6) 1775-1776; DOI: 10.2337/dc13-0707

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The TODAY Study: An NIH Perspective on Its Implications for Research
Barbara L. Linder, Judith E. Fradkin, Griffin P. Rodgers
Diabetes Care Jun 2013, 36 (6) 1775-1776; DOI: 10.2337/dc13-0707
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?
  • Taking the Air Out of Oxygen Supplementation in Individuals With Diabetes and Acute Coronary Syndromes
  • The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.